Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

NEXT STORY
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
PREV STORY
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix in an Up-Market Transaction with a Share Exchange of GNBT Stock at $2.50

author_avatar
NASDAQ Market News

Evoke Pharma Completes Credit Facility Repayment

SOLANA BEACH, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the ...

author_avatar
NASDAQ Market News

Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018

Poster presentations will include new analysis of efficacy against drug resistant S. aureus in ...

author_avatar
NASDAQ Market News